Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study
This analysis provides key information on baseline disease characteristics of patients treated with oral systemics, including baricitinib. Most patients treated with oral systemics in AD-REAL had long-lasting disease, refractory to systemic therapies, with moderate skin affectation but severe itch and impact on quality of life. AD-REAL is the first study to show many patients in real-world practice who are treated with oral systemics present with BSA ≤ 40 and Itch NRS ≥ 7, and most of these patients were treated with JAKi.
Authors
- Andreas Pinter (ORCID: https://orcid.org/0000-0002-1330-1502)
- Matthias Augustin (ORCID: https://orcid.org/0000-0002-4026-8728)
- Mohamed Elrayes
- E. Serra‐Baldrich (ORCID: https://orcid.org/0000-0001-7603-0300)
- Inmaculada de la Torre (ORCID: https://orcid.org/0000-0002-0037-6134)
- Samuel Ogwu
- Susanne Grond (ORCID: https://orcid.org/0000-0002-7121-9013)
- Julien Sénéschal (ORCID: https://orcid.org/0000-0003-1139-0908)
- Αναστασία Λαμπροπούλου (ORCID: https://orcid.org/0000-0002-3627-9133)
- Anthony Bewley
Institutions
- Goethe University Frankfurt (DE)
- Universitat Autònoma de Barcelona (ES)
- Université de Bordeaux (FR)
- Queen Mary University of London (GB)
- Eli Lilly (United States) (US)
- Barts Health NHS Trust (GB)
- Hospital de Sant Pau (ES)
- University Hospital Frankfurt (DE)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1007/s12325-025-03137-3
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company